申请人:Murphy A Michael
公开号:US20050085555A1
公开(公告)日:2005-04-21
This invention relates to a process of synthesis and composition of open chain (ring), closed ring, linear branched and or substituted polyamines, polyamine derived tyrosine phosphatase inhibitors and PPAR partial agonists/partial antagonists via a series of substitution reactions and optimizing the bioavailability and biological activities of the compounds. Polyamines prevent the toxicty of neutoxins and diabetogenic toxins including paraquat, methyphenyl pyridine radical, rotenone, diazoxide, streptozotocin and alloxan. These polyamines can be to treat neurological, cardiovascular, endocrine acquired and inherited mitochondrial DNA damage diseases and other disorders in mammalian subjects, and more specifically to the therapy of Parkinson's disease, Alzheimer's disease, Lou Gehrig's disease, Binswanger's disease, Olivopontine Cerebellar Degeneration, Lewy Body disease, Diabetes, Stroke, Atherosclerosis, Myocardial Ischemia, Cardiomyopathy, Nephropathy, Ischemia, Glaucoma, Presbycussis, Cancer, Osteoporosis, Rheumatoid Arthritis, Inflammatory Bowel Disease, Multiple Sclerosis and as Antidotes to Toxin Exposure.
这项发明涉及一种合成和构成开链(环)、闭环、线性分支和/或取代聚胺、聚胺衍生的酪氨酸磷酸酶抑制剂和PPAR部分激动剂/部分拮抗剂的过程,通过一系列的取代反应来优化化合物的生物利用度和生物活性。聚胺可以预防神经毒素和导致糖尿病的毒素的毒性,包括百草枯、甲基苯基吡啶自由基、洛特侬、重组蛋白酶和阿洛克瑞。这些聚胺可以用于治疗哺乳动物主体中的神经系统、心血管系统、内分泌系统获得性和遗传性线粒体DNA损伤疾病以及其他疾病,更具体地用于治疗帕金森病、阿尔茨海默病、路易氏氏病、宾斯旺格氏病、橄榄桥小脑变性、Lewy小体病、糖尿病、中风、动脉粥样硬化、心肌缺血、心肌病、肾病、缺血、青光眼、老年性耳聋、癌症、骨质疏松症、类风湿性关节炎、炎症性肠病、多发性硬化症以及作为毒素暴露的解毒剂。